Arsenic compounds: Revived ancient remedies in the fight against human malignancies

Current Opinion in Chemical Biology

Volumn 16, Issue 1-2, 2012, Pages 92-98

  Liu, Jian Xiang ^a,b   Zhou, Guang Biao ^c   Chen, Sai Juan ^a,b   Chen, Zhu ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b Shanghai Jiao Tong University   (China)

^c INSTITUTE OF ZOOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; ASCORBIC ACID; BUSULFAN; CACODYLIC ACID; CYTARABINE; DARINAPARSIN; DAUNORUBICIN; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; MELARSOPROL; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETINOIC ACID; SUMO PROTEIN; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DIMERIZATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; ENZYME DEGRADATION; ESOPHAGUS CANCER; GENE TRANSLOCATION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHATIC LEUKEMIA; LYMPHOMA; MELANOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OVARY CANCER; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN MULTIMERIZATION; REVIEW; SOLID TUMOR; STOMACH CANCER; SUMOYLATION; TRADITIONAL MEDICINE; TRYPANOSOMIASIS; UBIQUITINATION; ZINC FINGER MOTIF;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 84862828134     PISSN: 13675931     EISSN: 18790402     Source Type: Journal    
DOI: 10.1016/j.cbpa.2012.01.015     Document Type: Review

References (78)

1. Tokar E.J., Benbrahim-Tallaa L., Ward J.M., Lunn R., Sams R.L., Waalkes M.P. Cancer in experimental animals exposed to arsenic and arsenic compounds. Crit Rev Toxicol 2010, 40:912-927.
2. Jomova K., Jenisova Z., Feszterova M., Baros S., Liska J., Hudecova D., Rhodes C.J., Valko M. Arsenic: toxicity, oxidative stress and human disease. J Appl Toxicol 2011, 31:95-107.
3. Waxman S., Anderson K.C. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001, 6(Suppl 2):3-10.
4. Emadi A., Gore S.D. Arsenic trioxide-an old drug rediscovered. Blood Rev 2010, 24:191-199.
5. Scheindlin S. The duplicitous nature of inorganic arsenic. Mol Interven 2005, 5:60-64.
6. Zhang T.D. Treatment of acute granulocytic leukemia with " Ai ling No 1" -clinical analysis and experimental research. Chin J Integr Chin West Med 1984, 4:19-20.
7. Sun H.D., Ma L., Hu X.C. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia. Chin J Integr Chin West Med 1992, 12:170-172.
8. 3) in the treatment of APL: II. Remission induction in relapsed patients and pharmacokinetics. Blood 1996, 88:3354-3360.
9. Niu C., Yan H., Yu T., Sun H.P., Liu J.X., Li X.S., Wu W., Zhang F.Q., Chen Y., Zhou L., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
10. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348.
11. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., Stone R.M., Kalaycio M., Scheinberg D.A., Steinherz P., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
12. Raffoux E., Rousselot P., Poupon J., Daniel M.-T., Cassinat B., Delarue R., Taksin A.-L., Réa D., Buzyn A., Tibi A., et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003, 21:2326-2334.
13. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004, 101:5328-5335.
14. Estey E., Garcia-Manero G., Ferrajoli A., Faderl S., Verstovsek S., Jones D., Kantarjian H. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006, 107:3469-3473.
15. Ravandi F., Estey E., Jones D., Faderl S., O'Brien S., Fiorentino J., Pierce S., Blamble D., Estrov Z., Wierda W., et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009, 27:504-510.
16. Zhou G., Zhang J., Wang Z., Chen S., Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil Trans R Soc B 2007, 362:959-971.
17. Mathews V., George B., Chendamarai E., Lakshmi K.M., Desire S., Balasubramanian P., Viswabandya A., Thirugnanam R., Abraham A., Shaji R.V., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010, 28:3866-3871.
18. Appelbaum F.R., Tallman M.S., Larson Stone R.A., Rowe J.M., Coutre S., Feusner J.H., Gregory J., Couban S., Powell B.L., Moser B., et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116:3751-3757.
19. Wang H., Chen X.Y., Wang B.S., Rong Z.X., Qi H., Chen H.Z. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leuk Res 2011, 35:1170-1177.
20. Chen S.-J., Zhou G.-B., Zhang X.-W., Mao J.-H., de Thé H., Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011, 117:6425-6437.
21. Dilda P.J., Hogg P.J. Arsenical-based cancer drugs. Cancer Treat Rev 2007, 33:542-564.
22. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
23. Huang M.E., Ye Y.C., Chen S.R., Zhao J.C., Gu L.J., Cai J.R., Zhao L., Xie J.X., Shen Z.X., Wang Z.Y. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases. Chin Med J (Engl) 1987, 100:949-953.
24. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
25. Wang Z.Y., Sun G.L., Lu J.X., Gu L.J., Huang M.E., Chen S.R. Treatment of acute promyelocytic leukemia with all-trans retinoic acid in China. Nouv Rev Fr Hematol 1990, 32:34-36.
26. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Woods W.G., Ogden A., Weinstein H., Shepherd L., Willman C., Bloomfield C.D., Rowe J.M., Wiernik P.H. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002, 100:4298-4302.
27. Sanz M.A., Montesinos P., Vellenga E., Rayón C., de la Serna J., Parody R., Bergua J.M., León A., Negri S., González M., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood 2008, 112:3130-3134.
28. Sanz M.A., Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011, 29:495-503.
29. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., Naoe T., Lengfelder E., Büchner T., Döhner H., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
30. Tallman M., Douer D., Gore S., Powell B.L., Ravandi F., Rowe J., Ranganathan A., Sanz M.A. Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy. Clin Lymphoma Myeloma Leuk 2010, 10(Suppl 3):S122-S126.
31. Hu J., Liu Y.F., Wu C.F., Xu F., Shen Z.X., Zhu Y.M., Li J.M., Tang W., Zhao W.L., Wu W., et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009, 106:3342-3347.
32. Powell B.L., Moser B., Stock W., Gallagher R.E., Willman C.L., Stone R.M., Rowe J.M., Coutre S., Feusner J.H., Gregory J., et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116:3751-3757.
33. Ravandi F. Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy. Oncology (Williston Park) 2011, 25:741-743.
34. Park J.H., Tallman M.S. Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology (Williston Park) 2011, 25:733-741.
35. Ferrara F. Acute promyelocytic leukemia: what are the treatment options?. Expert Opin Pharmacother 2010, 11:587-596.
36. Tsimberidou A.M., Kantarjian H., Keating M.J., Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?. Leuk Lymphoma 2006, 47:2282-2288.
37. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996, 88:1052-1061.
38. 3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
39. Carney D.A. Arsenic trioxide mechanisms of action-looking beyond acute promyelocytic leukemia. Leuk Lymphoma 2008, 49:1846-1851.
40. de Thé H., Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010, 10:775-783.
41. Nasr R., Lallemand-Breitenbach V., Zhu J., Guillemin M.C., de Thé H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin Cancer Res 2009, 15:6321-6326.
42. Zhang X.W., Yan X.J., Zhou Z.R., Yang F.F., Wu Z.Y., Sun H.B., Liang W.X., Song A.X., Lallemand-Breitenbach V., Jeanne M., et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010, 328:240-243.
43. 3. Cancer Cell 2010, 18:88-98.
44. 4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 2010, 107:21683-21688.
45. Zhang Q.Y., Mao J.H., Liu P., Huang Q.H., Lu J., Xie Y.Y., Weng L., Zhang Y., Chen Q., Chen S.J., Chen Z. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc Natl Acad Sci U S A 2009, 106:3378-3383.
46. Larochette N., Decaudin D., Jacotot E., Brenner C., Marzo I., Susin S.A., Zamzami N., Xie Z., Reed J., Kroemer G. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res 1999, 249:413-421.
47. Dai J., Weinberg R.S., Waxman S., Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999, 93:268-277.
48. Chou W.C., Jie C., Kenedy A.A., Jones R.J., Trush M.A., Dang C.V. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A 2004, 101:4578-4583.
49. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., Keating M.J., Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003, 278:37832-37839.
50. Sumi D., Shinkai Y., Kumagai Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol Appl Pharmacol 2010, 244:385-392.
51. Notte A., Leclere L., Michiels C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol 2011, 82:427-434.
52. Goussetis D.J., Altman J.K., Glaser H., McNeer J.L., Tallman M.S., Platanias L.C. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem 2010, 285:29989-29997.
53. Watson A.S., Mortensen M., Simon A.K. Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. Cell Cycle 2011, 10:1719-1725.
54. Azad M.B., Chen Y., Gibson S.B. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 2009, 11:777-790.
55. Bøe S.O., Simonsen A. Autophagic degradation of an oncoprotein. Autophagy 2010, 6:964-965.
56. Isakson P., Bjørås M., Bøe S.O., Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010, 116:2324-2331.
57. Becker M.W., Jordan C.T. Leukemia stem cells in 2010: current understanding and future directions. Blood Rev 2011, 25:75-81.
58. Annaloro C., Onida F., Saporiti G., Lambertenghi Deliliers G. Cancer stem cells in hematological disorders: current and possible new therapeutic approaches. Curr Pharm Biotechnol 2011, 12:217-225.
59. Zheng X., Seshire A., Rüster B., Bug G., Beissert T., Puccetti E., Hoelzer D., Henschler R., Ruthardt M. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica 2007, 92:323-331.
60. Ablain J., de Thé H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 2011, 117:5795-5802.
61. Welch J.S., Yuan W., Ley T.J. PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. J Clin Invest 2011, 121:1636-1645.
62. Park J.W., Choi Y.J., Jang M.A., Baek S.H., Lim J.H., Passaniti T., Kwon T.K. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 2001, 286:726-734.
63. Roboz G.J., Dias S., Lam G., Lane W.J., Soignet S.L., Warrell R.P., Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000, 96:1525-1530.
64. Lew Y.S., Brown S.L., Griffin R.J., Song C.W., Kim J.H. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999, 59:6033-6037.
65. Takahashi S. Combination therapy with arsenic trioxide for hematological malignancies. Anticancer Agents Med Chem 2010, 10:504-510.
66. Sekeres M.A. Arsenic trioxide as a treatment for myelodysplastic syndrome. Curr Hematol Malig Rep 2006, 1:34-38.
67. Röllig C., Illmer T. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer Treat Rev 2009, 35:425-430.
68. Litzow M.R. Arsenic trioxide. Expert Opin Pharmacother 2008, 9:1773-1785.
69. 4) and its recent development as an anticancer agent. J Ethnopharmacol 2011, 135:595-602.
70. Wang L., Zhou G.B., Liu P., Song J.H., Liang Y., Yan X.J., Xu F., Wang B.S., Mao J.H., Shen Z.X., et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A 2008, 105:4826-4831.
71. Sun F., Chen N.N., Cheng Y.B. Compound realgar and natural indigo tablets in treatment of acute promyelocytic leukemia: a summary of experience in 204 cases. Zhong Xi Yi Jie He Xue Bao 2008, 6:639-642. (in Chinese).
72. Soignet S.L., Tong W.P., Hirschfeld S., Warrell R.P. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 1999, 44:417-421.
73. Don A.S., Kisker O., Dilda P., Donoghue N., Zhao X., Decollogne S., Creighton B., Flynn E., Folkman J., Hogg P.J. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003, 3:497-509.
74. Duzkale H., Jilani I., Orsolic N., Zingaro R.A., Golemovic M., Giles F.J., Kantarjian H., Albitar M., Freireich E.J., Verstovsek S. In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. Cancer Chemother Pharmacol 2003, 51:427-432.
75. Mann K.K., Wallner B., Lossos I.S., Miller W.H. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs 2009, 18:1727-1734.
76. Matulis S.M., Morales A.A., Yehiayan L., Croutch C., Gutman D., Cai Y., Lee K.P., Boise L.H. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther 2009, 8:1197-1206.
77. Wu J., Henderson C., Feun L., Van Veldhuizen P., Gold P., Zheng H., Ryan T., Blaszkowsky L.S., Chen H., Costa M., et al. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs 2010, 28:670-676.
78. Tsimberidou A.M., Camacho L.H., Verstovsek S., Ng C., Hong D.S., Uehara C.K., Gutierrez C., Daring S., Stevens J., Komarnitsky P.B., et al. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res 2009, 15:4769-4776.